argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

News
July 19, 2023
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

Amsterdam, the Netherlands

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 27, 2023 at 2:30 pm CET (8:30 am ET) to discuss its half year 2023 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

Belgium32 800 50 201
France33 800 943355
Netherlands31 20 795 1090
United Kingdom  44 800 358 0970
United States1 888 415 4250
Japan81 3 4578 9081
Switzerland41 43 210 11 32


About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Erin Murphy
emurphy@argenx.com

Investors:

Alexandra Roy (US)
ARoy@argenx.com

Lynn Elton (EU)
LElton@argenx.com